Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimer's Disease
Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimer's Disease
批准号:
8846525
负责人:
P. Hemachandra Reddy
金额:
$36.27万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-15 至 2019-04-30
关键词:
ATP Synthesis PathwayAffectAgeAlzheimer&aposs DiseaseAmyloid beta-ProteinAutopsyBehaviorBiochemicalBiological AssayBrainCarrier ProteinsCerebral cortexCo-ImmunoprecipitationsCognitiveDefectDigitoninDisease ProgressionDissociationFractionationFree RadicalsFunctional disorderGlycogen Synthase Kinase 3Glycogen Synthase KinasesGoalsGuanosine Triphosphate PhosphohydrolasesHydrogen PeroxideImmunoblottingLeadLinkLipid PeroxidationMembraneMembrane ProteinsMethodsMitochondriaMorphologyMusNerve DegenerationNeuronal DysfunctionNeuronsOutcomeOuter Mitochondrial MembraneOxidative PhosphorylationOxidative StressPathogenesisPathologyPatientsPermeabilityPhosphorylationPhosphotransferasesPhysiologicalPlayProductionProteinsRelative (related person)ReportingResearchResearch PersonnelRespirationRoleStagingStructureSynapsesTissuesTransgenic MiceVoltage-Dependent Anion ChannelVoltage-Dependent_Anion_Channel-1Wild Type Mousebasebrain tissuecytochrome c oxidasehexokinaseinsightmind controlmitochondrial dysfunctionprotein metabolitepublic health relevanceresearch studytau Proteinstau-1therapy development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The long-term goal of the proposed research is to understand the role of the voltage-dependent anion
channel 1 (VDAC1) protein in Alzheimer's disease (AD) pathogenesis. Recent studies using postmortem AD
brains, brain tissues from 6-, 12-, and 24-month-old A¿PP transgenic mice, and primary neurons from A¿PP
and tau mice revealed that age, amyloid beta (A¿)-, and phosphorylated (phospho) tau-induced mitochondrial
dysfunction and oxidative stress are key factors involved in neuronal dysfunction in AD pathogenesis.
Researchers have reported that A¿ is associated with mitochondria localized at synapses and with synaptic
damage and mitochondrial dysfunction. Preliminary research revealed that VDAC1, located in the outer
membrane of mitochondria, was higher in the cortical tissues from AD patients and was also higher in the
cerebral cortices of the 6-, 12-, and 24-month-old A¿PP mice. Research also revealed VDAC1 interacting with
A¿ and phospho tau in the AD postmortem brains and in the cerebral cortices from APP, APPxPS1, and
3xAD.Tg mice. Mitochondrial functional analysis indicated increased free radicals, lipid peroxidation levels, and
fission-linked GTPase activity, and decreased cytochrome oxidase and ATP levels in the APP transgenic mice.
Preliminary research also indicated that A¿-induced activated glycogen synthase kinase 3¿ (GSK3¿) reduced
hexokinases 1 and 2, and enhanced VDAC1 phosphorylation, leading to defects in mitochondrial
structure/function. However, the links between A¿ and VDAC1 and between phospho tau and VDAC1 are
unclear, and the relationship between GSK3¿ and VDAC1 phosphorylation to mitochondrial dysfunction are
unclear. One hypothesis is that A¿ and phospho tau interact with VDAC1, which disrupts the transport of
proteins/metabolites, resulting in defects in oxidative phosphorylation and in ATP synthesis. Another
hypothesis is that a partial deficiency of VDAC1 maintains the mitochondrial pore activity in neurons producing
A¿ and phospho tau, which in turn reduce mitochondrial dysfunction/synaptic damage in AD neurons.
The proposed research objective is to determine the role of VDAC1 in mitochondrial dysfunction in
relation to A¿ and phospho tau in AD pathogenesis. To this end, the proposed specific aims are: 1) to
determine the physiological relevance of the interactions between VDAC1 and A¿, and between VDAC1 and
phosphorylated tau in relation to VDAC1 phosphorylation and hexokinase reductions in AD neurons, 2) to
determine whether reduced VDAC1 maintains mitochondrial pore activity and mitochondrial function in neurons
producing A¿ and 3) phosphorylated tau. The outcomes of the experiments for these aims will provide new
insights into the physiological relevance of increased levels of VDAC1 and its interactions with A¿ and
phosphorylated tau in AD pathogenesis~ and will provide critical information that can be used to develop
therapies for reducing A¿- and phosphorylated tau-induced mitochondrial damage and neuronal dysfunction in
AD patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RLIP, Mitochondrial Dysfunction in Alzheimer’s Disease
-
批准号:10901025
-
项目类别:
-
资助金额:$57.2万
-
财政年份:2023
-
负责人:P. Hemachandra Reddy
-
依托单位:
MicroRNA Mouse Models and Alzheimer’s Disease
-
批准号:10526166
-
项目类别:
-
资助金额:$186.23万
-
财政年份:2022
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Molecules in Alzheimer's Disease and Other Tauopathies
-
批准号:10836888
-
项目类别:
-
资助金额:$38.21万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Molecules and Alzheimer's Disease
-
批准号:10625074
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Molecules as Therapeutic Drugs for Alzheimer's Disease
-
批准号:10602413
-
项目类别:
-
资助金额:$65.11万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
MicroRNA-455-3p and Alzheimer's Disease
-
批准号:10230768
-
项目类别:
-
资助金额:$58.57万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Molecules as Therapeutic Drugs for Alzheimer's Disease
-
批准号:10374919
-
项目类别:
-
资助金额:$65.11万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Molecules as Therapeutic Drugs for Alzheimer's Disease
-
批准号:10223188
-
项目类别:
-
资助金额:$65.11万
-
财政年份:2020
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Fragmentation and Neurodegeneration in Huntington's Disease
-
批准号:9472711
-
项目类别:
-
资助金额:$37.83万
-
财政年份:2017
-
负责人:P. Hemachandra Reddy
-
依托单位:
Mitochondrial Fragmentation and Neurodegeneration in Huntington's Disease
-
批准号:9757824
-
项目类别:
-
资助金额:$37.83万
-
财政年份:2017
-
负责人:P. Hemachandra Reddy
-
依托单位:
Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimer's Disease
-
批准号:8723663
-
项目类别:
-
资助金额:$10.2万
-
财政年份:2014
-
负责人:P. Hemachandra Reddy
-
依托单位:
Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimer's Disease
-
批准号:8989634
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2014
-
负责人:P. Hemachandra Reddy
-
依托单位:
Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimer's Disease
-
批准号:9272303
-
项目类别:
-
资助金额:$37.39万
-
财政年份:2014
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:8554759
-
项目类别:
-
资助金额:$41.24万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:8451085
-
项目类别:
-
资助金额:$43.97万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:8989642
-
项目类别:
-
资助金额:$39.28万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:8661671
-
项目类别:
-
资助金额:$4.36万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:9059560
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer's Disease
-
批准号:8841650
-
项目类别:
-
资助金额:$36.53万
-
财政年份:2012
-
负责人:P. Hemachandra Reddy
-
依托单位:
NEUROPROTECTIVE EFFECTS OF DIMEBON IN ALZHEIMER'S DISEASE
-
批准号:8357825
-
项目类别:
-
资助金额:$4.36万
-
财政年份:2011
-
负责人:P. Hemachandra Reddy
-
依托单位:
海外基金